Exagen (NASDAQ:XGN) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.18) by 11.11 percent. This is unchanged from the same period last year. The company reported quarterly sales of $16.631 million which beat the analyst consensus estimate of $16.567 million by 0.39 percent. This is a 21.79 percent increase over sales of $13.655 million the same period last year.